INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics
GET POWR RATINGS... FREE!
INMB POWR Grades
- Sentiment is the dimension where INMB ranks best; there it ranks ahead of 51.68% of US stocks.
- INMB's strongest trending metric is Momentum; it's been moving down over the last 179 days.
- INMB ranks lowest in Value; there it ranks in the 5th percentile.
INMB Stock Summary
- INMB's price/sales ratio is 876.38; that's higher than the P/S ratio of 99.53% of US stocks.
- With a year-over-year growth in debt of 9,411.8%, Inmune Bio Inc's debt growth rate surpasses 99.67% of about US stocks.
- As for revenue growth, note that INMB's revenue has grown 1,558.12% over the past 12 months; that beats the revenue growth of 99.34% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Inmune Bio Inc are BBIO, OTIC, ASND, VIR, and FIXX.
- Visit INMB's SEC page to see the company's official filings. To visit the company's web site, go to www.inmunebio.com.
INMB Valuation Summary
- INMB's price/earnings ratio is -21.9; this is 160% lower than that of the median Healthcare stock.
- Over the past 31 months, INMB's price/sales ratio has gone NA NA.
- INMB's price/sales ratio has moved NA NA over the prior 31 months.
Below are key valuation metrics over time for INMB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INMB | 2021-08-31 | 38172.7 | 9.7 | -21.9 | -20.6 |
| INMB | 2021-08-30 | 36372.7 | 9.3 | -20.9 | -19.6 |
| INMB | 2021-08-27 | 32236.4 | 8.2 | -18.5 | -17.2 |
| INMB | 2021-08-26 | 31027.3 | 7.9 | -17.8 | -16.5 |
| INMB | 2021-08-25 | 30227.3 | 7.7 | -17.4 | -16.1 |
| INMB | 2021-08-24 | 31527.3 | 8.0 | -18.1 | -16.8 |
INMB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INMB has a Quality Grade of D, ranking ahead of 11.03% of graded US stocks.
- INMB's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows INMB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -3.952 |
| 2021-03-31 | 0 | 1 | -15.163 |
| 2020-12-31 | 0 | 1 | -22.264 |
| 2020-09-30 | 0 | NA | -21.947 |
| 2020-06-30 | 0 | NA | -15.048 |
| 2020-03-31 | 0 | NA | -9.777 |
INMB Price Target
For more insight on analysts targets of INMB, see our INMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.75 | Average Broker Recommendation | 1.38 (Strong Buy) |
INMB Stock Price Chart Interactive Chart >
INMB Price/Volume Stats
| Current price | $7.49 | 52-week high | $30.37 |
| Prev. close | $7.16 | 52-week low | $6.18 |
| Day low | $6.94 | Volume | 101,449 |
| Day high | $7.51 | Avg. volume | 142,417 |
| 50-day MA | $7.68 | Dividend yield | N/A |
| 200-day MA | $12.72 | Market Cap | 134.42M |
INmune Bio Inc. - Common stock (INMB) Company Bio
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.
Latest INMB News From Around the Web
Below are the latest news stories about Inmune Bio Inc that investors may wish to consider to help them evaluate INMB as an investment opportunity.
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 3, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021 and to provide a corp |
INmune Bio, Inc. to Present at the BIO CEO & Investor ConferenceBOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the BIO CEO & Investor Conference being held February 14 – 17 at the Marriott Marquis in New York City. BIO CEO & Investor Conference Presentation Date: Tuesday, February 15, 2022Pres |
Does INmune Bio (NASDAQ:INMB) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Maxim Group Thinks Inmune Bio’s Stock is Going to RecoverMaxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio (INMB – Research Report) on February 2 and set a price target of $22.00. The company's shares closed last Friday at $10.36, close to its 52-week low of $7.88. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Inmune Bio is a Moderate Buy with an average price target of $21.00, implying an 114.9% upside from current levels. |
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal CancerBoca Raton, Florida, Jan. 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune™ -- the company’s pseudokine NK cell priming platform -- in nasopharyngeal cancer (NPC), a type of |
INMB Price Returns
| 1-mo | N/A |
| 3-mo | -31.72% |
| 6-mo | -45.37% |
| 1-year | -25.47% |
| 3-year | -30.78% |
| 5-year | N/A |
| YTD | -26.57% |
| 2021 | -40.77% |
| 2020 | 196.90% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...